|
Aug 8
|
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
|
|
Aug 7
|
Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 6
|
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
|
|
Jul 28
|
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
|
|
Jul 22
|
FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink
|
|
Jul 14
|
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
|
|
Jun 30
|
US High Growth Tech Stocks with Promising Potential
|
|
Jun 26
|
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
|
|
Jun 25
|
No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital
|
|
Jun 25
|
Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright
|
|
Jun 24
|
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
|
|
Jun 21
|
Capricor Therapeutics announces four-year data from HOPE-2 OLE study
|
|
Jun 20
|
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
|
|
Jun 17
|
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
|
|
Jun 12
|
Capricor says FDA inspection brought Form 483 with several observations
|
|
Jun 11
|
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
|
|
May 22
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
May 7
|
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
|
|
May 6
|
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
|
|
Apr 17
|
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?
|